DE3587045T2 - Substituierte imidazol-derivate und verfahren zu deren herstellung und deren anwendung. - Google Patents
Substituierte imidazol-derivate und verfahren zu deren herstellung und deren anwendung.Info
- Publication number
- DE3587045T2 DE3587045T2 DE8888106210T DE3587045T DE3587045T2 DE 3587045 T2 DE3587045 T2 DE 3587045T2 DE 8888106210 T DE8888106210 T DE 8888106210T DE 3587045 T DE3587045 T DE 3587045T DE 3587045 T2 DE3587045 T2 DE 3587045T2
- Authority
- DE
- Germany
- Prior art keywords
- inden
- dihydro
- methyl
- imidazole
- ethanone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title description 178
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 22
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 10
- 150000002367 halogens Chemical class 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims 2
- -1 R4 is H Chemical group 0.000 abstract description 14
- 150000003839 salts Chemical class 0.000 abstract description 8
- 239000002253 acid Substances 0.000 abstract description 6
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 125000003342 alkenyl group Chemical group 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 239000002464 receptor antagonist Substances 0.000 abstract description 2
- 229940044551 receptor antagonist Drugs 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 81
- 150000002460 imidazoles Chemical class 0.000 description 79
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 238000005160 1H NMR spectroscopy Methods 0.000 description 40
- 125000003118 aryl group Chemical group 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- 238000002844 melting Methods 0.000 description 26
- 230000008018 melting Effects 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 20
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 20
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 16
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 16
- 229910052794 bromium Inorganic materials 0.000 description 16
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 16
- JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 15
- 229960001894 detomidine Drugs 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000000556 agonist Substances 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- TYYCRMLBQARGGU-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)ethanone Chemical compound C1=CC=C2CC(C(=O)C)CC2=C1 TYYCRMLBQARGGU-UHFFFAOYSA-N 0.000 description 6
- RBEKONHDQBHXEG-UHFFFAOYSA-N 2-bromo-1-(2-bromo-1-methyl-1,3-dihydroinden-2-yl)ethanone Chemical compound C1=CC=C2CC(C(=O)CBr)(Br)C(C)C2=C1 RBEKONHDQBHXEG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- HISOCHCBRJDPLE-UHFFFAOYSA-N 1-(3,5-dimethyl-1h-inden-2-yl)ethanone Chemical compound CC1=CC=C2CC(C(=O)C)=C(C)C2=C1 HISOCHCBRJDPLE-UHFFFAOYSA-N 0.000 description 5
- TUKGSBTVYWYLDH-UHFFFAOYSA-N 3,7-dimethyl-1h-indene-2-carboxylic acid Chemical compound C1=CC=C(C)C2=C1C(C)=C(C(O)=O)C2 TUKGSBTVYWYLDH-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- XZYJILCUWKZAEE-UHFFFAOYSA-N 2-bromo-1-(1,2,3,4-tetrahydronaphthalen-2-yl)ethanone Chemical compound C1=CC=C2CC(C(=O)CBr)CCC2=C1 XZYJILCUWKZAEE-UHFFFAOYSA-N 0.000 description 4
- AMIZKLZQTJLBOZ-UHFFFAOYSA-N 2-bromo-1-(2-bromo-1,4-dimethyl-1,3-dihydroinden-2-yl)ethanone Chemical compound C1=CC(C)=C2CC(C(=O)CBr)(Br)C(C)C2=C1 AMIZKLZQTJLBOZ-UHFFFAOYSA-N 0.000 description 4
- DLKKDQSXTJVVMW-UHFFFAOYSA-N 2-bromo-1-(2-bromo-3,4-dihydro-1h-naphthalen-2-yl)ethanone Chemical compound C1=CC=C2CC(C(=O)CBr)(Br)CCC2=C1 DLKKDQSXTJVVMW-UHFFFAOYSA-N 0.000 description 4
- WHZZUKQNXKOSOF-UHFFFAOYSA-N 2-bromo-1-(2-ethyl-3,4-dihydro-1h-naphthalen-2-yl)ethanone Chemical compound C1=CC=C2CC(CC)(C(=O)CBr)CCC2=C1 WHZZUKQNXKOSOF-UHFFFAOYSA-N 0.000 description 4
- SBPPNTYSOJCMDG-UHFFFAOYSA-N 2-bromo-1-(2-methyl-1,3-dihydroinden-2-yl)ethanone Chemical compound C1=CC=C2CC(C)(C(=O)CBr)CC2=C1 SBPPNTYSOJCMDG-UHFFFAOYSA-N 0.000 description 4
- UROBYOZITOSHIB-UHFFFAOYSA-N 2-bromo-1-(3,5-dimethyl-1h-inden-2-yl)ethanone Chemical compound C1=C(C)C=C2C(C)=C(C(=O)CBr)CC2=C1 UROBYOZITOSHIB-UHFFFAOYSA-N 0.000 description 4
- OIKDESVHCFBNCU-UHFFFAOYSA-N 2-bromo-1-(3,7-dimethyl-1h-inden-2-yl)ethanone Chemical compound C1=CC=C(C)C2=C1C(C)=C(C(=O)CBr)C2 OIKDESVHCFBNCU-UHFFFAOYSA-N 0.000 description 4
- OJGQVOARYFNMJA-UHFFFAOYSA-N 2-ethyl-3,4-dihydro-1h-naphthalene-2-carboxylic acid Chemical compound C1=CC=C2CC(CC)(C(O)=O)CCC2=C1 OJGQVOARYFNMJA-UHFFFAOYSA-N 0.000 description 4
- VWCCBMWZNOWFDT-UHFFFAOYSA-N 2-methyl-1,3-dihydroindene-2-carboxylic acid Chemical compound C1=CC=C2CC(C)(C(O)=O)CC2=C1 VWCCBMWZNOWFDT-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 101100311330 Schizosaccharomyces pombe (strain 972 / ATCC 24843) uap56 gene Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- RMOPJLIMRSAIMD-UHFFFAOYSA-N methyl 2,3-dihydro-1h-indene-2-carboxylate Chemical compound C1=CC=C2CC(C(=O)OC)CC2=C1 RMOPJLIMRSAIMD-UHFFFAOYSA-N 0.000 description 4
- 229960001802 phenylephrine Drugs 0.000 description 4
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 4
- 229960001289 prazosin Drugs 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 101150018444 sub2 gene Proteins 0.000 description 4
- GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 4
- 229960000317 yohimbine Drugs 0.000 description 4
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 4
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 3
- BFNNILWMWUHDPW-UHFFFAOYSA-N 1-(2-ethyl-3,4-dihydro-1h-naphthalen-2-yl)ethanone Chemical compound C1=CC=C2CC(CC)(C(C)=O)CCC2=C1 BFNNILWMWUHDPW-UHFFFAOYSA-N 0.000 description 3
- IJSOSJWYLCKYOU-UHFFFAOYSA-N 1-(2-methyl-1,3-dihydroinden-2-yl)ethanone Chemical compound C1=CC=C2CC(C(=O)C)(C)CC2=C1 IJSOSJWYLCKYOU-UHFFFAOYSA-N 0.000 description 3
- LWXPISRHFLBLQC-UHFFFAOYSA-N 1-(3,7-dimethyl-1h-inden-2-yl)ethanone Chemical compound C1=CC(C)=C2CC(C(=O)C)=C(C)C2=C1 LWXPISRHFLBLQC-UHFFFAOYSA-N 0.000 description 3
- QETZSZNCWLMCSR-UHFFFAOYSA-N 2-bromo-1-(2,3-dihydro-1h-inden-2-yl)ethanone Chemical compound C1=CC=C2CC(C(=O)CBr)CC2=C1 QETZSZNCWLMCSR-UHFFFAOYSA-N 0.000 description 3
- ZJPWEMVJFPRQQY-UHFFFAOYSA-N 2-ethyl-3,4-dihydro-1h-naphthalene-2-carbonyl chloride Chemical compound C1=CC=C2CC(CC)(C(Cl)=O)CCC2=C1 ZJPWEMVJFPRQQY-UHFFFAOYSA-N 0.000 description 3
- ADXIETBHTNTTFH-UHFFFAOYSA-N 2-methyl-1,3-dihydroindene-2-carbonyl chloride Chemical compound C1=CC=C2CC(C)(C(Cl)=O)CC2=C1 ADXIETBHTNTTFH-UHFFFAOYSA-N 0.000 description 3
- GYNRSVPBBSCRSP-UHFFFAOYSA-N 3,5-dimethyl-1h-indene-2-carboxylic acid Chemical compound C1=C(C)C=C2C(C)=C(C(O)=O)CC2=C1 GYNRSVPBBSCRSP-UHFFFAOYSA-N 0.000 description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 102000017910 Adrenergic receptor Human genes 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000031709 bromination Effects 0.000 description 3
- 238000005893 bromination reaction Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- TWBVCTUXOVAZFA-UHFFFAOYSA-N methyl 2-ethyl-3,4-dihydro-1h-naphthalene-2-carboxylate Chemical compound C1=CC=C2CC(CC)(C(=O)OC)CCC2=C1 TWBVCTUXOVAZFA-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- WQXDRWLUNDERNE-UHFFFAOYSA-N 1-(1,2,3,4-tetrahydronaphthalen-2-yl)ethanone Chemical compound C1=CC=C2CC(C(=O)C)CCC2=C1 WQXDRWLUNDERNE-UHFFFAOYSA-N 0.000 description 2
- UHJQMPGREBGBGX-UHFFFAOYSA-N 1-(1,4-dimethyl-2,3-dihydro-1h-inden-2-yl)ethanone Chemical compound C1=CC=C(C)C2=C1C(C)C(C(C)=O)C2 UHJQMPGREBGBGX-UHFFFAOYSA-N 0.000 description 2
- NVRNCBWTEDOAQA-UHFFFAOYSA-N 1-(1-benzofuran-2-yl)-2-bromoethanone Chemical compound C1=CC=C2OC(C(=O)CBr)=CC2=C1 NVRNCBWTEDOAQA-UHFFFAOYSA-N 0.000 description 2
- IIKLOUOOEVKQDU-UHFFFAOYSA-N 1-(2-bromo-1-methyl-1,3-dihydroinden-2-yl)ethanone Chemical class C1=CC=C2CC(C(C)=O)(Br)C(C)C2=C1 IIKLOUOOEVKQDU-UHFFFAOYSA-N 0.000 description 2
- VQEDMDWIBFEVTB-UHFFFAOYSA-N 1-(2-ethyl-1-methyl-1,3-dihydroinden-2-yl)ethanone Chemical compound C1=CC=C2C(C)C(CC)(C(C)=O)CC2=C1 VQEDMDWIBFEVTB-UHFFFAOYSA-N 0.000 description 2
- JTSLSLQDTSTIKT-UHFFFAOYSA-N 2-bromo-1-(2-ethyl-1-methyl-1,3-dihydroinden-2-yl)ethanone Chemical compound C1=CC=C2C(C)C(CC)(C(=O)CBr)CC2=C1 JTSLSLQDTSTIKT-UHFFFAOYSA-N 0.000 description 2
- WPSKYNGHIWKPAF-UHFFFAOYSA-N 2-ethyl-1-methyl-1,3-dihydroindene-2-carboxylic acid Chemical compound C1=CC=C2C(C)C(CC)(C(O)=O)CC2=C1 WPSKYNGHIWKPAF-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 101100108551 Mus musculus Akr1b7 gene Proteins 0.000 description 2
- 208000006550 Mydriasis Diseases 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000729 antidote Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- YKWNUSJLICDQEO-UHFFFAOYSA-N ethoxyethane;propan-2-ol Chemical compound CC(C)O.CCOCC YKWNUSJLICDQEO-UHFFFAOYSA-N 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- IAJCTSSNCSYJPW-UHFFFAOYSA-N methyl 1,2,3,4-tetrahydronaphthalene-2-carboxylate Chemical compound C1=CC=C2CC(C(=O)OC)CCC2=C1 IAJCTSSNCSYJPW-UHFFFAOYSA-N 0.000 description 2
- ZNLCIXZCKRPBHM-UHFFFAOYSA-N methyl 2-ethyl-1-methyl-1,3-dihydroindene-2-carboxylate Chemical compound C1=CC=C2C(C)C(CC)(C(=O)OC)CC2=C1 ZNLCIXZCKRPBHM-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- BLGXFZZNTVWLAY-DIRVCLHFSA-N rauwolscine Chemical compound C1=CC=C2C(CCN3C[C@H]4CC[C@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-DIRVCLHFSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- GBZFILBGEYHYAE-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalene-2-carbonyl chloride Chemical compound C1=CC=C2CC(C(=O)Cl)CCC2=C1 GBZFILBGEYHYAE-UHFFFAOYSA-N 0.000 description 1
- NTAGXJQHJQUOOA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalene-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)CCC2=C1 NTAGXJQHJQUOOA-UHFFFAOYSA-N 0.000 description 1
- QWFMWRCVEIGICZ-UHFFFAOYSA-N 1,6-dimethyl-1h-indene-2-carboxylic acid Chemical compound C1=C(C)C=C2C(C)C(C(O)=O)=CC2=C1 QWFMWRCVEIGICZ-UHFFFAOYSA-N 0.000 description 1
- MHEXBQVMIIXBLW-UHFFFAOYSA-N 1-(1,6-dimethyl-1h-inden-2-yl)ethanone Chemical compound C1=C(C)C=C2C(C)C(C(C)=O)=CC2=C1 MHEXBQVMIIXBLW-UHFFFAOYSA-N 0.000 description 1
- YUTFQTAITWWGFH-UHFFFAOYSA-N 1-(1-benzofuran-2-yl)ethanone Chemical compound C1=CC=C2OC(C(=O)C)=CC2=C1 YUTFQTAITWWGFH-UHFFFAOYSA-N 0.000 description 1
- JAFDSAQMVCFDEW-UHFFFAOYSA-N 1-(2,5-dimethyl-1,3-dihydroinden-2-yl)ethanone Chemical compound C1=C(C)C=C2CC(C(=O)C)(C)CC2=C1 JAFDSAQMVCFDEW-UHFFFAOYSA-N 0.000 description 1
- IKUVPUAXZRBUDA-UHFFFAOYSA-N 1-(2-ethyl-5-methyl-1,3-dihydroinden-2-yl)ethanone Chemical compound C1=C(C)C=C2CC(CC)(C(C)=O)CC2=C1 IKUVPUAXZRBUDA-UHFFFAOYSA-N 0.000 description 1
- YEZPDEMBUVTABP-UHFFFAOYSA-N 1-(5-methyl-2,3-dihydro-1h-inden-2-yl)ethanone Chemical compound C1=C(C)C=C2CC(C(=O)C)CC2=C1 YEZPDEMBUVTABP-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- XLGARFKPWXQTCC-UHFFFAOYSA-N 2,2-diethoxy-n-piperidin-1-ylacetamide Chemical compound CCOC(OCC)C(=O)NN1CCCCC1 XLGARFKPWXQTCC-UHFFFAOYSA-N 0.000 description 1
- XUDCMQBOWOLYCF-UHFFFAOYSA-N 2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)CC2=C1 XUDCMQBOWOLYCF-UHFFFAOYSA-N 0.000 description 1
- VBLGDNBKWAGELE-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-2-yl)-2,2-diethoxyacetaldehyde Chemical compound C1=CC=C2CC(C(OCC)(C=O)OCC)CC2=C1 VBLGDNBKWAGELE-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- NPHULPIAPWNOOH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2,3-dihydroindol-1-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCC2=CC=CC=C12 NPHULPIAPWNOOH-UHFFFAOYSA-N 0.000 description 1
- HVTQDSGGHBWVTR-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-phenylmethoxypyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound C(C1=CC=CC=C1)OC1=NN(C=C1C=1C=NC(=NC=1)NC1CC2=CC=CC=C2C1)CC(=O)N1CCOCC1 HVTQDSGGHBWVTR-UHFFFAOYSA-N 0.000 description 1
- VXZBYIWNGKSFOJ-UHFFFAOYSA-N 2-[4-[5-(2,3-dihydro-1H-inden-2-ylamino)pyrazin-2-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC=1N=CC(=NC=1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 VXZBYIWNGKSFOJ-UHFFFAOYSA-N 0.000 description 1
- QUIWSCUJFRGKMD-UHFFFAOYSA-N 2-acetyl-2,3-dihydroinden-1-one Chemical compound C1=CC=C2C(=O)C(C(=O)C)CC2=C1 QUIWSCUJFRGKMD-UHFFFAOYSA-N 0.000 description 1
- YAENKTFGFXAVKD-UHFFFAOYSA-N 2-acetyl-2-ethyl-3h-inden-1-one Chemical compound C1=CC=C2C(=O)C(CC)(C(C)=O)CC2=C1 YAENKTFGFXAVKD-UHFFFAOYSA-N 0.000 description 1
- ZURXNXKDXQKTLM-UHFFFAOYSA-N 2-bromo-1-(2-bromo-1,3-dihydroinden-2-yl)ethanone Chemical compound C1=CC=C2CC(C(=O)CBr)(Br)CC2=C1 ZURXNXKDXQKTLM-UHFFFAOYSA-N 0.000 description 1
- APYDCTAPNKFTRB-UHFFFAOYSA-N 2-bromo-2,3-dihydro-1h-indene Chemical compound C1=CC=C2CC(Br)CC2=C1 APYDCTAPNKFTRB-UHFFFAOYSA-N 0.000 description 1
- KVQCOGYOXAWTOW-UHFFFAOYSA-N 2-ethyl-1-methyl-1,3-dihydroindene-2-carbonyl chloride Chemical compound C1=CC=C2C(C)C(CC)(C(Cl)=O)CC2=C1 KVQCOGYOXAWTOW-UHFFFAOYSA-N 0.000 description 1
- KNRGKQOTWZSHNQ-UHFFFAOYSA-N 3,5-dimethyl-1h-indene-2-carbonyl chloride Chemical compound C1=C(C)C=C2C(C)=C(C(Cl)=O)CC2=C1 KNRGKQOTWZSHNQ-UHFFFAOYSA-N 0.000 description 1
- BAHHBERKDYESQK-UHFFFAOYSA-N 3,7-dimethyl-1h-indene-2-carbonyl chloride Chemical compound C1=CC=C(C)C2=C1C(C)=C(C(Cl)=O)C2 BAHHBERKDYESQK-UHFFFAOYSA-N 0.000 description 1
- KVJORUBRGGRSNU-UHFFFAOYSA-N 5-(5-bromo-2,3-dihydro-1-benzofuran-2-yl)-1h-imidazole;hydrochloride Chemical compound Cl.C1C2=CC(Br)=CC=C2OC1C1=CNC=N1 KVJORUBRGGRSNU-UHFFFAOYSA-N 0.000 description 1
- ONMRGUYFBWOGJB-UHFFFAOYSA-N C(C)C1(C(C2=CC=CC=C2C1)C)C(=O)Cl.C(C)C1(C(C2=CC=CC=C2C1)C)C(=O)Cl Chemical compound C(C)C1(C(C2=CC=CC=C2C1)C)C(=O)Cl.C(C)C1(C(C2=CC=CC=C2C1)C)C(=O)Cl ONMRGUYFBWOGJB-UHFFFAOYSA-N 0.000 description 1
- MZKXVCFDSKNWKK-UHFFFAOYSA-N C(C)OC(CC(=O)O)=O.C(C)O[Mg] Chemical compound C(C)OC(CC(=O)O)=O.C(C)O[Mg] MZKXVCFDSKNWKK-UHFFFAOYSA-N 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AINBZKYUNWUTRE-UHFFFAOYSA-N ethanol;propan-2-ol Chemical compound CCO.CC(C)O AINBZKYUNWUTRE-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- XBKZCOOJZSZDOB-UHFFFAOYSA-N ethyl 2-[(2-methylphenyl)methyl]-3-oxobutanoate Chemical compound CCOC(=O)C(C(C)=O)CC1=CC=CC=C1C XBKZCOOJZSZDOB-UHFFFAOYSA-N 0.000 description 1
- PGMCRCMQNWICNI-UHFFFAOYSA-N ethyl 2-[(4-methylphenyl)methyl]-3-oxobutanoate Chemical compound CCOC(=O)C(C(C)=O)CC1=CC=C(C)C=C1 PGMCRCMQNWICNI-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- NBEMQPLNBYYUAZ-UHFFFAOYSA-N ethyl acetate;propan-2-one Chemical compound CC(C)=O.CCOC(C)=O NBEMQPLNBYYUAZ-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- UPRXAOPZPSAYHF-UHFFFAOYSA-N lithium;cyclohexyl(propan-2-yl)azanide Chemical compound CC(C)N([Li])C1CCCCC1 UPRXAOPZPSAYHF-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- FZJCXIDLUFPGPP-UHFFFAOYSA-N propan-2-ol;toluene Chemical compound CC(C)O.CC1=CC=CC=C1 FZJCXIDLUFPGPP-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Lubricants (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Epoxy Resins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
- Golf Clubs (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08429578A GB2167408B (en) | 1984-11-23 | 1984-11-23 | Substituted imidazole derivatives and their preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3587045D1 DE3587045D1 (de) | 1993-03-11 |
| DE3587045T2 true DE3587045T2 (de) | 1993-06-03 |
Family
ID=10570140
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8888106210T Expired - Fee Related DE3587045T2 (de) | 1984-11-23 | 1985-11-21 | Substituierte imidazol-derivate und verfahren zu deren herstellung und deren anwendung. |
| DE8585308491T Expired DE3574252D1 (en) | 1984-11-23 | 1985-11-21 | Substituted imidazole derivatives and their preparation and use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8585308491T Expired DE3574252D1 (en) | 1984-11-23 | 1985-11-21 | Substituted imidazole derivatives and their preparation and use |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US4689339A (enExample) |
| EP (2) | EP0310745B1 (enExample) |
| JP (1) | JPH064597B2 (enExample) |
| KR (1) | KR930004673B1 (enExample) |
| AT (2) | ATE85050T1 (enExample) |
| AU (2) | AU586839B2 (enExample) |
| BG (1) | BG60762B2 (enExample) |
| CA (1) | CA1268770C (enExample) |
| DD (1) | DD258230A1 (enExample) |
| DE (2) | DE3587045T2 (enExample) |
| DK (2) | DK164903C (enExample) |
| ES (2) | ES8704462A1 (enExample) |
| FI (1) | FI80264C (enExample) |
| GB (1) | GB2167408B (enExample) |
| GR (1) | GR852817B (enExample) |
| HK (1) | HK3592A (enExample) |
| HU (1) | HU195189B (enExample) |
| IE (1) | IE58165B1 (enExample) |
| IL (1) | IL77111A (enExample) |
| NO (1) | NO166585C (enExample) |
| NZ (1) | NZ214258A (enExample) |
| PH (1) | PH22016A (enExample) |
| PT (1) | PT81542B (enExample) |
| SG (1) | SG106891G (enExample) |
| SU (1) | SU1424736A3 (enExample) |
| ZA (1) | ZA858942B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4891431A (en) * | 1986-01-28 | 1990-01-02 | Mitsui Petrochemical Industries, Ltd. | Process for preparing 2-unsubstituted imidazoles |
| FI862039A0 (fi) * | 1986-05-15 | 1986-05-15 | Farmos Oy | Nytt foerfarande foer framstaellning av 4(5)-substituerade imidazolderivat. |
| FI81092C (fi) * | 1986-05-15 | 1990-09-10 | Farmos Oy | Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat. |
| JP2576493B2 (ja) * | 1987-03-20 | 1997-01-29 | アイシン精機株式会社 | 原稿読取り装置に用いられる原稿トレ− |
| FR2621327B1 (fr) * | 1987-10-06 | 1990-01-05 | Commissariat Energie Atomique | Procede de production et d'extraction de polysaccharides a partir d'une culture de porphyridium cruentum et dispositif pour la mise en oeuvre du procede |
| GB2225782A (en) * | 1988-12-09 | 1990-06-13 | Farmos Group Limited | Imidazole derivatives useful for treatment of diabetes |
| GB8903437D0 (en) * | 1989-02-15 | 1989-04-05 | Erba Carlo Spa | Imidazolyl derivatives of 3,4-dihydro-2h-1-benzothiopyran |
| CA1321751C (en) * | 1989-02-21 | 1993-08-31 | Eugene C. Crichlow | Mechanism mediating ruminal stasis in ruminal lactic acidosis |
| DK344489D0 (da) * | 1989-07-12 | 1989-07-12 | Novo Nordisk As | Substituerede 2-imidazoliner og fremstilling og anvendelse deraf |
| GB2244431A (en) * | 1990-05-31 | 1991-12-04 | Farmos Oy | Treatment of age related memory impairment and other cognitive disorders |
| GB2256135B (en) | 1991-05-31 | 1995-01-18 | Orion Yhtymae Oy | Transdermal administration of 4-substituted imidazoles |
| US5541211A (en) * | 1991-06-18 | 1996-07-30 | Orion-Yhtyma Oy | Administration of atipamezole to elicit a yohimbine-like alpha-adrenoreceptor antagonistic noradrenergic transmission |
| CZ287406B6 (cs) * | 1991-11-05 | 2000-11-15 | Smithkline Beecham Corporation | Indanové a indenové deriváty, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
| GB9127050D0 (en) * | 1991-12-20 | 1992-02-19 | Orion Yhtymae Oy | Substituted imidazole derivatives and their preparation and use |
| GB9127430D0 (en) * | 1991-12-27 | 1992-02-19 | Scras | Benzofuranylimidazole derivatives |
| GB9312669D0 (en) | 1993-06-18 | 1993-08-04 | Orion Yhtymae Oy | New opticla isomers |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| FR2733983B1 (fr) * | 1995-05-10 | 1997-08-01 | Pf Medicament | Procede de preparation d'un derive d'acide benzofurane carboxylque optiquement pur et son utilisation pour preparer l'efaroxan |
| GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| FR2754709B1 (fr) | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
| EP0986530A1 (en) * | 1997-06-05 | 2000-03-22 | Venantius Limited | Indane compounds and their pharmaceutical use |
| AU3378399A (en) * | 1998-04-02 | 1999-10-25 | Ortho-Mcneil Pharmaceutical, Inc. | 4-thionaphthyl-1h-imidazoles with alpha-2-adrenergic activity |
| FR2784989B1 (fr) * | 1998-09-10 | 2002-09-27 | Fabre Pierre Sante | Derive d'ester d'acide 2-ethyl-2,3-dihydrobenzofurane- carboxylique, procede de preparation et utilisation pour la preparation de derives de l'efaroxan |
| WO2000042023A1 (en) * | 1999-01-18 | 2000-07-20 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| US6388090B2 (en) * | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
| US6593324B2 (en) | 2000-03-01 | 2003-07-15 | Orion Corporation | Dervatives of quinoline as alpha-2 antagonists |
| PT1280779E (pt) * | 2000-05-08 | 2005-11-30 | Orion Corp | Novos indanilimidazois policiclicos com actividade adrenergica alfa2 |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US6543389B2 (en) | 2001-06-26 | 2003-04-08 | Pfizer Inc. | Insecticidal pet collar |
| EA008537B1 (ru) | 2002-04-03 | 2007-06-29 | Орион Корпорейшн | Полициклические соединения как эффективные антагонисты альфа2-адренорецептора |
| US8188126B2 (en) | 2002-05-16 | 2012-05-29 | Pierre Fabre Medicament | Imidazolic compounds and use thereof as alpha-2 adrenergic receptors |
| FI116292B (fi) * | 2003-01-08 | 2005-10-31 | Juvantia Pharma Ltd Oy | Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita |
| WO2005041950A1 (en) * | 2003-11-04 | 2005-05-12 | Akzo Nobel N.V. | Ectoparasiticidal formulations of spinosyns and azole pesticides |
| FI20050657A0 (fi) * | 2005-06-17 | 2005-06-17 | Orion Corp | Atipametsolin kiteytysmenetelmä |
| CN101287470B (zh) | 2005-10-12 | 2012-10-17 | 优尼麦德药物股份有限公司 | 改良的睾酮凝胶及使用方法 |
| US7592461B2 (en) * | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| ATE459251T1 (de) * | 2006-08-08 | 2010-03-15 | Intervet Int Bv | Zusammensetzung für verstärkte antiparasitische wirksamkeit |
| TWI457122B (zh) | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物 |
| CL2008003553A1 (es) * | 2007-12-05 | 2009-11-27 | Grindeks Jsc | Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso |
| JP6446054B2 (ja) | 2013-11-05 | 2018-12-26 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | ゴマ油ベースの注射製剤 |
| AR104882A1 (es) | 2015-06-05 | 2017-08-23 | Orion Corp | DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C |
| EP3370718B1 (en) * | 2015-11-05 | 2021-01-27 | University Of Louisville Research Foundation, Inc. | Local and regional anesthesia and analgesia |
| CN109415355A (zh) | 2016-06-29 | 2019-03-01 | 奥赖恩公司 | 苯并二噁烷衍生物及其药物用途 |
| AU2019411230B2 (en) | 2018-12-21 | 2025-04-17 | Société des Produits Nestlé S.A. | Nutritional composition for inducing a feeling of satiety, a better sleep and/or limiting nocturnal awaking in infants or young children |
| CN111978254A (zh) * | 2019-05-22 | 2020-11-24 | 南京康德祥医药科技有限公司 | 一种阿替美唑盐酸盐的制备工艺 |
| CN111925330A (zh) * | 2020-09-07 | 2020-11-13 | 上海阿达玛斯试剂有限公司 | 一种阿替美唑的制备方法 |
| LU103072B1 (en) | 2023-02-15 | 2024-08-19 | Univ Ljubljani | N,N-DIALKYL-4-(2-ETHYLINDAN-2-YL)-lH-IMIDAZOLE-l-CARBOXAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES |
| EP4658639A1 (en) | 2023-02-01 | 2025-12-10 | Univerza V Ljubljani | N,n-dialkyl-4-(2-ethylindan-2-yl)-1h-imidazole-1-carboxamides and related compounds for treatment of neurodegenerative diseases |
| CN117186010A (zh) * | 2023-08-15 | 2023-12-08 | 厦门欧瑞捷生物科技有限公司 | 一种盐酸阿替美唑的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2933962A1 (de) * | 1979-08-22 | 1981-03-26 | Hoechst Ag, 65929 Frankfurt | Verfahren zur herstellung von 4,5-dichlor-imidazolen. |
| IL62122A0 (en) * | 1980-03-04 | 1981-03-31 | Erba Farmitalia | N-imidazolyl derivatives of 1-chroman,their preparation and pharmaceutical compositions containing them |
| US4302469A (en) * | 1980-09-10 | 1981-11-24 | Syntex (U.S.A.) Inc. | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants |
| ZW13782A1 (en) * | 1981-07-28 | 1982-10-06 | Reckitt & Colmann Prod Ltd | Imidazoline derivatives |
| ES523609A0 (es) * | 1982-07-05 | 1985-03-01 | Erba Farmitalia | Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos. |
| FR2539415B1 (fr) * | 1983-01-14 | 1985-09-13 | Adir | Derives de la d-2 imidazoline, leur preparation et leur application en therapeutique |
| FR2542738A1 (fr) * | 1983-03-18 | 1984-09-21 | Synthelabo | Indanyl-2 d2-imidazoline, procede pour la preparer, et compositions pharmaceutiques qui la contiennent |
-
1984
- 1984-11-23 GB GB08429578A patent/GB2167408B/en not_active Expired
-
1985
- 1985-11-05 FI FI854335A patent/FI80264C/fi not_active IP Right Cessation
- 1985-11-18 CA CA 495608 patent/CA1268770C/xx not_active Expired - Lifetime
- 1985-11-20 NZ NZ214258A patent/NZ214258A/xx unknown
- 1985-11-20 IL IL77111A patent/IL77111A/xx not_active IP Right Cessation
- 1985-11-20 AU AU50083/85A patent/AU586839B2/en not_active Expired
- 1985-11-20 DD DD85283044A patent/DD258230A1/de not_active IP Right Cessation
- 1985-11-21 EP EP88106210A patent/EP0310745B1/en not_active Expired - Lifetime
- 1985-11-21 KR KR1019850008704A patent/KR930004673B1/ko not_active Expired - Fee Related
- 1985-11-21 EP EP85308491A patent/EP0183492B1/en not_active Expired
- 1985-11-21 AT AT88106210T patent/ATE85050T1/de not_active IP Right Cessation
- 1985-11-21 US US06/800,192 patent/US4689339A/en not_active Expired - Lifetime
- 1985-11-21 IE IE292985A patent/IE58165B1/en not_active IP Right Cessation
- 1985-11-21 PH PH33077A patent/PH22016A/en unknown
- 1985-11-21 ZA ZA858942A patent/ZA858942B/xx unknown
- 1985-11-21 GR GR852817A patent/GR852817B/el unknown
- 1985-11-21 DE DE8888106210T patent/DE3587045T2/de not_active Expired - Fee Related
- 1985-11-21 DE DE8585308491T patent/DE3574252D1/de not_active Expired
- 1985-11-21 AT AT85308491T patent/ATE47997T1/de not_active IP Right Cessation
- 1985-11-22 DK DK540485A patent/DK164903C/da not_active IP Right Cessation
- 1985-11-22 SU SU853979907A patent/SU1424736A3/ru active
- 1985-11-22 HU HU854471A patent/HU195189B/hu unknown
- 1985-11-22 NO NO854671A patent/NO166585C/no unknown
- 1985-11-22 JP JP60263586A patent/JPH064597B2/ja not_active Expired - Lifetime
- 1985-11-22 PT PT81542A patent/PT81542B/pt unknown
- 1985-11-22 ES ES549178A patent/ES8704462A1/es not_active Expired
-
1986
- 1986-12-29 ES ES557268A patent/ES8801248A1/es not_active Expired
-
1989
- 1989-04-21 AU AU33329/89A patent/AU3332989A/en not_active Abandoned
-
1991
- 1991-12-17 SG SG1068/91A patent/SG106891G/en unknown
-
1992
- 1992-01-09 HK HK35/92A patent/HK3592A/en not_active IP Right Cessation
- 1992-05-04 DK DK92582A patent/DK58292D0/da not_active Application Discontinuation
-
1994
- 1994-01-18 BG BG098378A patent/BG60762B2/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3587045T2 (de) | Substituierte imidazol-derivate und verfahren zu deren herstellung und deren anwendung. | |
| DE68913487T2 (de) | Piperazine-Derivate. | |
| DE69127260T2 (de) | Therapeutische heterocyclische verbindungen | |
| DE3212682C2 (enExample) | ||
| DE69225240T2 (de) | Substituierte imidazol derivate und deren herstellung und verwendung | |
| DE69321875T2 (de) | Benzimidezolderivate mit antidiabetischer und Anti-Plättchenklumpungswirkung | |
| DE68908392T2 (de) | Aminomethyl-chroman- und -thiochroman-verbindungen. | |
| DE2317710A1 (de) | Dopaminderivate | |
| DE68913673T2 (de) | Substituierte Imidazol-Derivate und Verfahren zu deren Herstellung und Anwendung. | |
| DE69301357T2 (de) | Indol derivate als "5-ht1-like" agonisten | |
| DE69819266T2 (de) | Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten | |
| DE69012031T2 (de) | Optisch aktive Benzylalkoholverbindung und pharmazeutische Zusammensetzung. | |
| DE69013994T2 (de) | Aromatische und heteroaromatische Amine zur Behandlung von Depressionen, Hirnleistungsstörungen und Dementia. | |
| DE69501791T2 (de) | Indol-derivate als 5-ht1-like agonisten | |
| DE2507429C2 (de) | Aminosäureester, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE69632032T2 (de) | Gefässverschliessende substituierte 2,3- dihydro -1,4- dioxinopyridine | |
| CH615665A5 (en) | Process for the preparation of the Z-isomer of 3-(4-bromophenyl)-N-methyl-3-(3-pyridyl)allylamine | |
| CH513883A (de) | Verfahren zur Herstellung von 1,3-Äthano-Piperazin | |
| DE2240599C3 (de) | Carbazol-Derivate, Verfahren zu deren Herstellung und Arzneimittel | |
| DE961166C (de) | Verfahren zur Herstellung von therapeutisch wirksamen substituierten 2, 6, 6-Trimethylcyclohexen-(1)-yl-(1)-propyl- oder -butylaminen bzw. deren Salzen und quaternaeren Ammoniumverbindungen | |
| DE69901522T2 (de) | Benzozyclobutanverbindungen, deren Herstellungsverfahren und diese enthaltende pharmazeutische Zusammenstellungen | |
| DE2034588B2 (de) | ej-Dimethoxy^-benzylisochinoline, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE2126169C3 (de) | Alkanolaminderivate und sie enthaltende pharmazeutische Zusammensetzungen | |
| DE1007774B (de) | Verfahren zur Herstellung von substituierten therapeutisch wirksamen 2, 6, 6-Trimethylcyclohexen-(1)-yl-(1)-propyl- oder -butylaminen bzw. deren Salzen oder quaternaerenAmmoniumverbindungen | |
| DE1249881B (de) | Verfahren zur Herstellung von Phenylathanolammen und deren Salzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |